Presentation is loading. Please wait.

Presentation is loading. Please wait.

Optimization of Anti-Thymocyte Globulin Administration Schedule in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation 

Published byสมพร ชินวัตร Modified over 5 years ago

Similar presentations

Presentation on theme: "Optimization of Anti-Thymocyte Globulin Administration Schedule in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation "— Presentation transcript:

1 Optimization of Anti-Thymocyte Globulin Administration Schedule in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation  Gary Lee Simmons, Anatevka Ribeiro, Roy Sabo, Kelly G. Hawks, May Aziz, Christina M. Wiedl, William B. Clark, Harold M. Chung, John M. McCarty, Catherine H. Roberts, Amir A. Toor  Biology of Blood and Marrow Transplantation  Volume 24, Issue 3, Pages S333-S334 (March 2018) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Overall Survival by Treatment Groups
Biology of Blood and Marrow Transplantation  , S333-S334DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Figure 2 Time to Relapse by Treatment Groups
Biology of Blood and Marrow Transplantation  , S333-S334DOI: ( /j.bbmt ) Copyright © Terms and Conditions

4 Figure 3 Time to Relapse by ddCD3
Biology of Blood and Marrow Transplantation  , S333-S334DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Optimization of Anti-Thymocyte Globulin Administration Schedule in Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation "

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Hideki Nakasone, MD, PhD, David B

Hideki Nakasone, MD, PhD, David B
Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole  Megan R. Barajas, Kristen.

Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole  Megan R. Barajas, Kristen.
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation 
Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.

Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.
Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,

Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,
Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia 

Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia 
Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes  Amir A.

Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes  Amir A.
Case Report: 52 Year-Old Male 11 Months after MUD for Angionimmunoblastic T Cell Lymphoma Developed Acute Fibrinous Organizing Pneumonitis Successfully.

Case Report: 52 Year-Old Male 11 Months after MUD for Angionimmunoblastic T Cell Lymphoma Developed Acute Fibrinous Organizing Pneumonitis Successfully.
Betty T. Tran, Abigail Halperin, Jason W. Chien 

Betty T. Tran, Abigail Halperin, Jason W. Chien 

Similar presentations

Ads by Google